Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Dave Chenn
AddedMar 31, 2024
UpdatedMay 31, 2026
Dave Chenn

Dave Chenn

Founder & CEO, Oceanpine Capital

Crunchbase

Dave Chenn's Career

Oceanpine Capital
Oceanpine Capital

Beijing, Beijing, CN

Founder & CEO· C-Suite · Management
Immune-Onc Therapeutics
Immune-Onc Therapeutics

Palo Alto, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Dave Chenn's Career

Oceanpine Capital
Oceanpine Capital
Investment FirmInvestment Firm1752018Beijing, Beijing, CN
Founder & CEO· C-Suite · Management
Immune-Onc Therapeutics
Immune-Onc Therapeutics
Public$140.1M352016Palo Alto, CA, US
Board Member· Board

Leadership at Immune-Onc Therapeutics

Bing YaoBing YaoBoard Member
Barbara KlenckeBarbara KlenckeBoard Member
Guo-Liang YuGuo-Liang YuCo-Founder
Greg CosmaGreg CosmaBoard Member
Austin GurneyAustin GurneyBoard Member
Charlene LiaoCharlene LiaoBoard Member

Similar to Immune-Onc Therapeutics

Immunitas TherapeuticsImmunitas TherapeuticsWaltham, MA, USCancer Therapeuticsest. 2019Immunitas TherapeuticsWaltham, MA, US · est. 2019

US-based Immunitas advances immuno-oncology therapeutics through an integrated genomics platform.

Series B · $97M33
Iovance BiotherapeuticsIovance BiotherapeuticsSan Carlos, CA, USCancer Therapiesest. 2007Iovance BiotherapeuticsSan Carlos, CA, US · est. 2007

Iovance Biotherapeutics: A California-based biotech firm specializing in novel cancer immunotherapies.

Public503
OncoResponseOncoResponseSeattle, WA, USBiomedical Servicesest. 2016OncoResponseSeattle, WA, US · est. 2016

OncoResponse Inc: A US-based biomedical services provider specializing in cancer care research and development.

Series B · $130.1M20
INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17

Dave Chenn's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakHaeil YiHaeil YiCo-Founder · DunamuLee Sirg-OoLee Sirg-OoCEO · Dunamu

People Similar to Dave Chenn

Tim SullivanTim SullivanCEO · Oceanic PartnersBrian SullivanBrian SullivanCEO · Five Oceans CapitalLi WeiLi WeiCo-Founder · Green Pine Capital PartnersLiu HaoLiu HaoCo-Founder · Green Pine Capital PartnersFrank ChiuFrank ChiuCo-Founder · P2P CapitalJ. Eric DavisJ. Eric DavisBoard Member · Skyepack